Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis

Omadacycline, vancomycin, and rifampin, as well as rifampin combination therapies, were evaluated in an experimental rat model of methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. All treatment groups had less MRSA recovered than saline-treated animals. The emergence of rifampin resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Karau, Melissa J., Schmidt-Malan, Suzannah M., Cunningham, Scott A., Mandrekar, Jayawant N., Pritt, Bobbi S., Keepers, Tiffany R., Serio, Alisa W., Chitra, Surya, Patel, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765317/
https://www.ncbi.nlm.nih.gov/pubmed/34723626
http://dx.doi.org/10.1128/AAC.01703-21
Descripción
Sumario:Omadacycline, vancomycin, and rifampin, as well as rifampin combination therapies, were evaluated in an experimental rat model of methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. All treatment groups had less MRSA recovered than saline-treated animals. The emergence of rifampin resistance was observed in 3 of 16 animals with rifampin monotherapy and none with rifampin combination therapy. After treatment, the median tibial bacterial loads were 6.04, 0.1, 4.81, and 5.24 log(10) CFU/g for saline-, rifampin-, vancomycin-, and omadacycline-treated animals, respectively. Omadacycline or vancomycin administered with rifampin yielded no detectable MRSA. Omadacycline administered with rifampin deserves evaluation in humans as a potential treatment for osteomyelitis.

Ejemplares similares